nach oben

PharmacoEconomics

Erschienen in:

01.04.2005 | Leading Article

Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis

verfasst von: Dr Mark A. Miller, Cathryn K. Shahab

Erschienen in: PharmacoEconomics | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Outbreaks of meningococcal disease have caused devastation worldwide. Effective vaccines have not been used routinely, due to perceived limitations of the duration of effectiveness as well as immunogenicity when administered during infancy. Given the sporadic nature of outbreaks, the optimal use of these vaccines to control both short-term epidemic and endemic meningococcal disease has been the subject of much debate.

Seven economic studies on the use of polysaccharide vaccination strategies help to highlight the relevant epidemiological and economic issues surrounding the decisions for their use. Five of these studies were based in Africa, the region where annual incidence rates can be several orders of magnitude greater than the rest of the world. These studies demonstrated that vaccination against meningococcal disease during outbreak situations is suboptimal given the inability to rapidly immunise populations in a timely fashion in resource-poor areas. However, depending on the disease incidence and the ability to deliver vaccines, the polysaccharide vaccine can be cost effective for preventive strategies when given prior to the start of outbreaks, either through presumptive vaccination or through a modified routine delivery strategy.

Economic analyses of mass immunisation campaigns and modelled routine vaccination suggest that routine use of meningococcal vaccines for preventive strategies could be within the range of cost-effective public health interventions in those regions of the world where meningococcal disease is endemic. This includes the meningococcal belt of Africa, the Sahelian region.

The use of trade names is for identification purposes only and does not imply endorsement.

Peltola H, Kataja JM, Makela PH. Shift in the age distribution of meningococcal disease as predictor of an epidemic? Lancet 1982; 11: 595–7CrossRef

Spanjaard L, Bol B, deMarie S, et al. Age distribution of meningococcal disease as predictor of epidemics. Lancet 1982; II: 1039–40CrossRef

Robbins J, Towne DW, Gotschlich EC, et al. [’Love’s labours lost’: failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet 1997; 350: 880–2PubMedCrossRef

Peltola H, Makela PH, Kayhty H, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297: 686–91PubMedCrossRef

Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus: IV. Immunogenicity of the group A and group C polysaccharides in human volunteers. J Exp Med 1969; 129: 1367–84

Frasch CE. Vaccines for prevention of meningococcal disease. Clin Microbiol Rev 1989; 2 Suppl.: S134–8PubMed

Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; II (8447): 114–8CrossRef

World Health Organization Working Group. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd ed. Geneva: World Health Organization, 1998

Centers for Disease Control. Recommendation of the Immunization Practices Advisory Committee: meningococcal vaccines. MMWR 1985; 34: 255-9

10.

Zhiqian M. Observation on the epidemiologic efficacy for 9 years on epidemic meningococcal polysaccharide vaccine of group A by district immunization method. Zhonghua Liu Xing Bing Xue Za Zhi 1991; 12: 69–71

11.

Win JJ. Changes in epidemic features of epidemic cerebrospinal meningitis after vaccination with purified meningococcal polysaccharide vaccine group A in Zhengzhou. Zhonghua Yu Fang Yi Xue Za Zhi 1993 May; 27 (3): 160–1

12.

Lapeyssonnie L. La meningite cerebrospinale en Afrique. [Cerebrospinal meningitis in Africa]. Bull World Health Organ 1963; 28 Suppl.: 1–100PubMed

13.

Greenwood BM. Epidemiology of meningitis in tropical Africa. In: Williams JD, Burnie J, editors. Bacterial meningitis. 1st ed. London: Academic Press Inc., 1987: 61–91

14.

Greenwood BM, Blakebrough IS, Bradley AK, et al. Meningococcal disease and season in sub-Saharan Africa. Lancet 1984; 1 (8390): 1339–42PubMedCrossRef

15.

Campagne G, Schuchat A, Djibo S, et al. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ 1999; 77: 499–508PubMed

16.

Merlin M, Martet G, Debonne JM, et al. Controle d’une epidemie de meningite a meningocoque en Afrique centrale. [Control of an epidemic of meningococcal meningitis in Central Africa]. Same 1996; 6: 87–95

17.

Heyman SN, Ginosar Y, Niel L, et al. Meningococcal meningitis among Rwandan refugees: diagnosis, management, and outcome in a field hospital. Int J Infect Dis 1998; 2: 137–42PubMedCrossRef

18.

Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health burden and control. World Health Star Q 1997; 50: 170–7

19.

Minutes of a WHO informal consultation on operational research on immunization prevention and control strategies for meningococcal disease; 1997 Feb 18-19; Annecy, France. Geneva: World Health Organization. WHO/EMC.97.2

20.

Moore PS, Plikaytis BD, Bolan GA, et al. Detection of meningitis epidemics in Africa: a population-based analysis. Int J Epidemiol 1992; 21: 155–62PubMedCrossRef

21.

Taha MK, Parent Du Chatelet I, Schlumberger M, et al. Neisseria meningitidis serogroups WI 35 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002 Mar; 40 (3): 1083–4PubMedCrossRef

22.

Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to Group B meningococcal polysaccharide vaccines. J Infect Dis 1972; 126: 514–22PubMedCrossRef

23.

Kayhty H, Karanko V, Peltola H, et al. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Infect Dis 1980; 142: 861–8PubMedCrossRef

24.

Mohammed I, Onyemelukwe GC, Obineche EN, et al. Control of epidemic meningococcal meningitis by mass vaccination: II. Persistence of antibody four years after vaccination. J Infect 1984; 9: 197–202PubMedCrossRef

25.

Zangwill K-M, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994; 169: 847–52PubMedCrossRef

26.

Gold R, Lepow ML, Goldschneider I, et al. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979; 140: 690–7PubMedCrossRef

27.

Kayhty H, Karanko V, Peltola H, et al. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis for three years in infants and children. J Infect Dis 1980; 142: 861–8PubMedCrossRef

28.

WHO Technical Report Series. Requirements for meningococcal polysaccharide vaccine. Requirements for Biological Substances No. 23. 1976; 594: 50-75

29.

MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunization during early childhood. Vaccine 1999; 17: 3086–93PubMedCrossRef

30.

Lieberman JM, Chin SS, Wong VK, et al. Safety and immunogenicity of a serogroup A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: a randomized controlled trial. JAMA 1996; 275: 1499–503PubMedCrossRef

31.

Musgrove P. Cost-benefit analysis of a regional system for vaccination against pneumonia, meningitis type B, and typhoid fever. Bull Pan Am Health Organ 1992; 26 (2): 173–91PubMed

32.

Jackson LA, Schuchat A, Gorsky RD, et al. Should college students be vaccinated against meningococcal disease? A costbenefit analysis. Am J Public Health 1995 Jun; 85 (6): 843–5PubMedCrossRef

33.

Veeken H, Ritmeijer K, Hausman B. Priority during a meningitis epidemic: vaccination or treatment? Bull World Health Organ 1998; 76 (2): 135–41PubMed

34.

Varaine F, Caugant DA, Rion JY, et al. Meningitis outbreaks and vaccination strategy. Trans R Soc Trop Med Hyg 1997 Jan-Feb; 91 (1): 3–7PubMedCrossRef

35.

Miller MA, Wenger J, Rosenstein N, et al. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J 1999 Dec; 18 (12): 1051–9PubMedCrossRef

36.

Bovier PA, Wyss K, An HJ. A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries. Soc Sci Med 1999 May; 48 (9): 1205–20

37.

Parent du Chatelet I, Gessner BD, da Silva A. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine 2001 May 14; 19 (25-26): 3420–31PubMedCrossRef

38.

De Wals P, Dionne M, Douville-Fradet M, et al. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull World Health Organ 1996; 74 (4): 407–11PubMed

39.

Dure-Samin A, Mubina A, Azra Y. An epidemic of meningococcal disease in Karachi (Pakistan): a study of children. Acta Paediatr Jpn 1991 Jun; 33 (3): 352–6PubMedCrossRef

40.

Frasch CE. Prospects for the prevention of meningococcal disease: special reference to group B. Vaccine 1987 Mar; 5 (1): 34CrossRef

41.

Fogarty I, Cafferkey MT, Moloney AC. Meningococcal disease in the Republic of Ireland: 1995. Commun Dis Rep CDR Rev 1997 Jan 10; 7 (1): R9–13PubMed

42.

Gordon SM. Should all college-bound freshmen receive meningococcal vaccine?. Cleve Clin J Med 2001 Jan; 68 (1): 9–10PubMed

43.

Aboal Vinas JL, Farjas Abadia P, Zubizarreta Alberdi R, et al. Meningococcal C disease epidemic in Galicia 1996: the decision making process. Gac Sanit 1999 Jan-Feb; 13 (1): 62–9PubMed

44.

Cochi SL, Markowitz LE, Joshi DD, et al. Control of epidemic group A meningococcal meningitis in Nepal. Int J Epidemmil 1987 Mar; 16 (1): 91–7CrossRef

45.

Greenwood BM. Treatment and prevention of meningococcal disease. Trop Doct 1984 Apr; 14 (2): 61–6PubMed

46.

Greenwood BM, Wali SS. Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet 1980 Apr 5; 1 (8171): 729–32PubMedCrossRef

47.

Saxena SN, Rawal IJ, Tripathi KK, et al. Meningococcal vaccines in prevention and control of meningitis. Indian Pediatr 1985 Jun; 22 (6): 453–65PubMed

48.

Binkin N, Band J. Epidemic of meningococcal meningitis in Bamako, Mali: epidemiological features and analysis of vaccine efficacy. Lancet 1982 Aug 7; II (8293): 315–8CrossRef

49.

Report of the first hemispheric meeting on meningococcal disease. Bull Pan Am Health Organ 1976; 10 (2): 163-76

50.

Rey M, Lafaix C, Mar ID, et al. Epidemiologic aspects of purulent meningitis in tropical Africa (1052 cases observed in Dakar). Lyon Med 1972 Nov 26; 228 (18): 503–8PubMed

51.

Spanjaard L, Bol P, Ekker W, et al. The incidence of bacterial meningitis in The Netherlands: a comparison of three registration systems, 1977-1982. J Infect 1985 Nov; 11 (3): 259–68PubMedCrossRef

52.

Pinner RW, Onyango F, Perkins BA, et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989. J Infect Dis 1992; 166: 359–64PubMedCrossRef

53.

Lewis R, Nathan N, Diana L, et al. Timely detection of meningococcal meningitis in epidemics in Africa. Lancet 2001; 358: 287–93PubMedCrossRef

54.

Robbins JB, Schneerson R, Gotschlich EC. A rebuttal: epidemic and endemic meningococcal meningitis is sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr Infect Dis J 2000; 19 (10): 945–53PubMedCrossRef

55.

Miller MA, Hinman A. Economic analyses of vaccine policies. In: Plotkin S, Orenstein W, eds. Vaccines. 4th ed. Philadelphia (PA): WB Saunders Co, 2003: 1463–90

56.

Mohammed I, Nasidi A, Alkali AS, et al. A severe epidemic of meningococcal meningitis in Nigeria, 1996. Trans R Soc Trop Med Hyg 2000; 94: 265–70PubMedCrossRef

57.

Miller MA, Pisani E. The cost of unsafe injections. Bull World Health Organ 1999; 77 (10): 808–11PubMed

58.

Pecoul B, Chirac P, Trouiller P, et al. Access to essential drugs in poor countries: a lost battle? JAMA 1999 Jan 27; 281 (4): 361–7CrossRef

59.

Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000 Feb; 19 (2): 144–50PubMedCrossRef

Titel: Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis
verfasst von: Dr Mark A. Miller
Cathryn K. Shahab
Publikationsdatum: 01.04.2005
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 4/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523040-00004

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis

Abstract

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2005

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany

Meningococcal vaccination: Cui bono?

Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease

Future challenges for the economic evaluation of healthcare